$26.49
1.07% day before yesterday
Nasdaq, Dec 20, 10:01 pm CET
ISIN
US10806X1028
Symbol
BBIO
Sector
Industry

BridgeBio Pharma Inc Target price 2024 - Analyst rating & recommendation

BridgeBio Pharma Inc Classifications & Recommendation:

Buy
88%
Hold
12%

BridgeBio Pharma Inc Price Target

Target Price $49.43
Price $26.49
Potential
Number of Estimates 14
14 Analysts have issued a price target BridgeBio Pharma Inc 2025 . The average BridgeBio Pharma Inc target price is $49.43. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 17 analysts: 15 Analysts recommend BridgeBio Pharma Inc to buy, 2 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the BridgeBio Pharma Inc stock has an average upside potential 2025 of . Most analysts recommend the BridgeBio Pharma Inc stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 9.30 219.27
88.02% 2,257.72%
EBITDA Margin -6,375.81% -255.89%
972.37% 95.99%
Net Margin -8,026.99% -224.02%
911.67% 97.21%

13 Analysts have issued a sales forecast BridgeBio Pharma Inc 2024 . The average BridgeBio Pharma Inc sales estimate is

$219m
Unlock
. This is
0.69% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$233m 6.77%
Unlock
, the lowest is
$216m 0.81%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $9.3m 88.02%
2024
$219m 2,257.72%
Unlock
2025
$179m 18.45%
Unlock
2026
$430m 140.33%
Unlock
2027
$960m 123.38%
Unlock
2028
$1.7b 74.54%
Unlock

4 Analysts have issued an BridgeBio Pharma Inc EBITDA forecast 2024. The average BridgeBio Pharma Inc EBITDA estimate is

$-561m
Unlock
. This is
6.59% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-551m 4.67%
Unlock
, the lowest is
$-572m 8.63%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $-593m 28.44%
2024
$-561m 5.38%
Unlock
2025
$-595m 6.04%
Unlock
2026
$-354m 40.42%
Unlock

EBITDA Margin

2023 -6,375.81% 972.37%
2024
-255.89% 95.99%
Unlock
2025
-332.74% 30.03%
Unlock
2026
-82.49% 75.21%
Unlock

7 BridgeBio Pharma Inc Analysts have issued a net profit forecast 2024. The average BridgeBio Pharma Inc net profit estimate is

$-491m
Unlock
. This is
7.85% lower
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-444m 2.49%
Unlock
, the lowest is
$-518m 13.69%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-747m 21.17%
2024
$-491m 34.20%
Unlock
2025
$-725m 47.53%
Unlock
2026
$-611m 15.68%
Unlock
2027
$-369m 39.62%
Unlock
2028
$111m 129.96%
Unlock

Net Margin

2023 -8,026.99% 911.67%
2024
-224.02% 97.21%
Unlock
2025
-405.30% 80.92%
Unlock
2026
-142.20% 64.91%
Unlock
2027
-38.44% 72.97%
Unlock
2028
6.60% 117.17%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -3.95 -2.60
21.17% 34.18%
P/E negative
EV/Sales 28.92

7 Analysts have issued a BridgeBio Pharma Inc forecast for earnings per share. The average BridgeBio Pharma Inc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-2.60
Unlock
. This is
7.88% lower
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$-2.35 2.49%
Unlock
, the lowest is
$-2.74 13.69%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-3.95 21.17%
2024
$-2.60 34.18%
Unlock
2025
$-3.83 47.31%
Unlock
2026
$-3.23 15.67%
Unlock
2027
$-1.95 39.63%
Unlock
2028
$0.59 130.26%
Unlock

P/E ratio

Current -10.98 8.93%
2024
-10.19 7.19%
Unlock
2025
-6.91 32.19%
Unlock
2026
-8.19 18.52%
Unlock
2027
-13.57 65.69%
Unlock
2028
45.28 433.68%
Unlock

Based on analysts' sales estimates for 2024, the BridgeBio Pharma Inc stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

28.92
Unlock
and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of
22.83
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 29.12 96.58%
2024
28.92 0.68%
Unlock
2025
35.47 22.63%
Unlock
2026
14.76 58.39%
Unlock
2027
6.61 55.23%
Unlock
2028
3.79 42.71%
Unlock

P/S ratio

Current 22.99 96.83%
2024
22.83 0.68%
Unlock
2025
28.00 22.63%
Unlock
2026
11.65 58.39%
Unlock
2027
5.22 55.23%
Unlock
2028
2.99 42.71%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today